<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421148</url>
  </required_header>
  <id_info>
    <org_study_id>P05961</org_study_id>
    <secondary_id>EudraCT: 2004-003819-23</secondary_id>
    <secondary_id>19.4.306</secondary_id>
    <nct_id>NCT00421148</nct_id>
  </id_info>
  <brief_title>Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)</brief_title>
  <official_title>A Multi -Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Sugammadex and Placebo in Pediatric and Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to explore the dose-response relation of sugammadex given as a reversal agent at
           reappearance of T2 after 0.6 mg.kg-1 rocuronium in pediatric and adult subjects

        -  to explore the pharmacokinetics of sugammadex in pediatric and adult subjects, and to
           evaluate the safety of sugammadex in pediatric and adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2005</start_date>
  <completion_date type="Actual">June 2, 2006</completion_date>
  <primary_completion_date type="Actual">May 31, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start administration of sugammadex to recovery T4/T1 ratio to 0.9.</measure>
    <time_frame>after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start administration of sugammadex to recovery T4/T1 ratio to 0.7</measure>
    <time_frame>after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start administration of sugammadex to recovery T4/T1 ratio to 0.8.</measure>
    <time_frame>after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 0.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 2.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 4.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 0.5 mg/kg</intervention_name>
    <description>Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 0.5 mg/kg sugammadex will be given.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 1.0 mg/kg</intervention_name>
    <description>Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 1.0 mg/kg sugammadex will be given.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2.0 mg/kg</intervention_name>
    <description>Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 2.0 mg/kg sugammadex will be given.</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4.0 mg/kg</intervention_name>
    <description>Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 4.0 mg/kg sugammadex will be given.</description>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Org 25969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of placebo will be given.</description>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class 1 - 2, between the ages of 28 days and 65 years inclusive, and between the
             ages of 2 and 65 years inclusive for Germany and between the ages of 6 and 65 years
             inclusive for Finland

          -  Scheduled for general anesthesia with an anticipated duration of anesthesia of at
             least 60 minutes, without further need for muscle relaxation other than one single
             dose of 0.6 mg.kg-1 rocuronium

          -  Scheduled for surgical procedures in the supine position

          -  Subjects who, and/or whose parent(s) or legal guardian(s) have given written informed
             consent [or appropriate assent, if applicable]

        Exclusion Criteria:

          -  Known or suspected neuromuscular disorders impairing NMB and/or significant renal
             dysfunction, in Germany creatinine and blood urea nitrogen outside local reference
             ranges

          -  Known or suspected to have a (family) history of malignant hyperthermia

          -  Known or suspected to have an allergy to narcotics, muscle relaxants or other
             medication used during general anesthesia

          -  Use of medication expected to interfere with the rocuronium given in this trial, based
             on the dose and the time of administration

          -  Pregnancy

          -  Childbearing potential not using any of the following methods of birth control: condom
             or diaphragm with spermicide, vasectomized partner ( &gt; 6 months), IUD, abstinence

          -  Breast -feeding

          -  Prior participation in trial 19.4.306

          -  Participation in another clinical trial, not pre-approved by NV Organon, within 30
             days of entering into trial 19.4.306
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, Hermens Y, Mirakhur RK. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009 Feb;110(2):284-94. doi: 10.1097/ALN.0b013e318194caaa.</citation>
    <PMID>19194156</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

